New drug combination for advanced bile duct cancer in the liver

Plain-English translation of NCT06859684 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new combination of three treatments for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer in the liver). The combination includes and —two newer drugs that help your immune system fight cancer—plus a targeted chemotherapy called hepatic arterial infusion chemotherapy that is delivered directly to the liver. Researchers hope this combination will work better than standard treatments currently available.

Current standard treatments for this type of advanced cancer have limited effectiveness and don't help enough patients. By combining targeted chemotherapy delivered directly to the tumor with two newer immunotherapy drugs, doctors hope to give patients a better chance of responding to treatment and living longer.

Do you qualify?

You likely qualify if…

you have been diagnosed with intrahepatic cholangiocarcinoma that cannot be surgically removed or has spread to other parts of your body
you have not received any previous chemotherapy or systemic cancer treatment
your cancer came back more than 6 months after surgery, or it's been more than 6 months since you finished any chemotherapy or radiation after surgery
you are in good enough health overall to tolerate treatment (ECOG performance status of 0 or 1)
you have at least one measurable tumor that can be tracked on imaging scans

You likely don't qualify if…

you have very severe liver damage or liver failure (Child-Pugh Class C)
you have severe bleeding problems that cannot be corrected with treatment
you have an active hepatitis infection or severe infection that cannot be treated at the same time
you have severe weight loss, muscle wasting, or failure of multiple organs
you have significant yellowing of the skin or confusion from liver disease

What participation looks like

If you join this trial, you will receive the new three-drug combination as your first-line cancer treatment. The chemotherapy will be delivered directly into the blood vessel supplying your liver tumor, while the two immunotherapy medications will be given by injection or infusion. You will have regular clinic visits and imaging scans to monitor how well the treatment is working and to watch for side effects. The trial is small, enrolling 25 patients total, and your care team will carefully track your response to the treatment over time.

AI-generated summary from trial data · Jul 7, 2026 · Not medical advice

New drug combination for advanced bile duct cancer in the liver

What is this trial?

Do you qualify?

What participation looks like

Trial locations